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and Beth Ann Swan, PhD, CRNP, FAAN
Vitamin D deficiency is common in the general public and in patients with cancer. Optimizing vitamin D intake is increas-
ingly recognized in cancer risk reduction, particularly in decreasing colorectal cancer risk. Therefore, summarizing the cur-
rent evidence to promote best practices related to vitamin D intake and colorectal cancer risk reduction is important. The 
objectives of this article are to examine the current evidence regarding the impact of vitamin D on colorectal cancer risk 
reduction and provide practice recommendations for clinicians. Relevant research articles from 2002–2008 were retrieved 
from multiple electronic databases. Reference lists of relevant articles also were searched manually. Twenty-five research 
reports were selected for this article: 4 randomized, controlled trials; 11 cohort or case-control studies measuring serum 
25-OH-D levels; and 10 cohort studies reporting vitamin D intake. This review generated three themes: raising 25-OH-D 
levels to a vitamin D sufficient state (32–100 ng/ml) achieved colorectal cancer risk reduction, increasing the intake of 
vitamin D reduced colorectal cancer risk, and increasing vitamin D intake to 1,000 IU daily is safe and likely sufficient to 
raise serum 25-OH-D levels above 32 ng/ml to achieve colorectal cancer risk reduction. Several practice recommendations 
are suggested. 
Journal Club Article
Optimizing Vitamin D Status  
to Reduce Colorectal Cancer Risk:  
An Evidentiary Review
At a Glance
Vitamin D deficiency or insufficiency (less than 32 ng/ml or 80 	
nmol/L) is common in the general population and in patients 
with cancer. 
Current evidence suggests that optimizing serum 25-OH-D 	
levels to the normal range of 32–100 ng/ml is associated 
with colorectal cancer risk reduction.
Daily vitamin D intake of 1,000 IU is safe and likely sufficient 	
to reduce colorectal cancer risk.
Guiyun Zhou, MSN, CRNP, AOCNS®, is a nurse practitioner at Vita 
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ancer is one of the most dreaded diagnoses from a 
physiological, psychological, social, and spiritual 
standpoint. According to the American Cancer So-
ciety ([ACS], 2008), cancer is the second leading 
cause of death in the Untied States; about 1.5 mil-
lion Americans were diagnosed with some form of cancer in 
2008 and more than 500,000 died. In addition, the estimated 
overall cost of cancer care reached $219 billion in 2007 (ACS). 
Therefore, cancer prevention and risk reduction clearly are in 
the national interest. Healthcare providers in particular have a 
major responsibility in leading the fight against cancer by ac-
tively screening for cancer, treating cancer-predisposing condi-
tions in a timely manner, and educating the public about cancer 
prevention (including directly modifiable risk factors). Vitamin 
D deficiency is considered one such risk factor for many types 
of solid organ cancers, such as colorectal cancer, breast cancer, 
and ovarian cancer (Garland et al., 2006). 
Vitamin D deficiency is an epidemic health problem in the 
industrial world; an estimated 1 billion people have vitamin D 
deficiency (Cherniack, Levis, & Troen, 2008; Holick, 2007). In the 
United States, 25%–58% of adolescents and adults are deficient in 
vitamin D (Looker, Dawson-Hughes, Calvo, Gunter, & Sahyoun, 
2002). Among patients with cancer, the prevalence of vitamin 
See p. E17  
for journal  
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D deficiency is much higher, approaching 90% (Everett, 2008; 
Hershman et al., 2006; Li et al., 2007; Maddipatla et al., 2007). 
Since the late 1990s, studying vitamin D’s effect on cancer has 
been of increasing interest. Ecological studies have shown that 
heightened sun exposure decreases internal solid organ cancers 
(Boscoe & Schymura, 2006; Grant, 2007; Tuohimaa et al., 2007). 
Researchers also have observed that higher intake of vitamin 
D from diet, supplements, or both is associated with a lower 
risk of colorectal and breast cancers (Garland et al., 2006; Lin 
et al., 2007; Robien, Cutler, & Lazovich, 2007). A meta-analysis 
of 18 randomized, controlled trials (RCTs) demonstrated that 
vitamin D supplementation is associated with decreased total 
mortality rates from life-threatening conditions such as cancer, 
cardiovascular disease, and diabetes mellitus (Autier & Gandini, 
2007). Many studies have similarly demonstrated an inverse 
relationship between serum 25-OH-D levels and the risk of 
colorectal, breast, and prostate cancers (Garland et al., 2006). 
In addition, lower serum 25-OH-D levels are associated with 
higher overall mortality, colorectal cancer–specific mortality, 
and more advance-staged disease in breast cancer and colorectal 
cancer (Fakih & Sunga, 2006; Goodwin, Ennis, Pritchard, Koo, 
& Hood, 2008; Melamed, Michos, Post, & Astor, 2008; Ng et al., 
2008; Palmieri, MacGregor, Girgis, & Vigushin, 2006; Sieg, Sieg, 
Dreyhaup, & Schmidt-Gayk, 2006). 
The major research breakthrough demonstrating the direct 
cancer risk reduction by vitamin D intake was reported by 
Lappe, Travers-Gustafson, Davies, Recker, and Heaney (2007). 
Their RCT studied 1,179 postmenopausal women and found 
that taking 1,100 IU of vitamin D plus 1,400–1,500 mg of daily 
calcium for four years resulted in a 60%–77% overall cancer risk 
reduction. Following this report, the Canadian Cancer Society 
(2007) updated their vitamin D recommendation to 1,000 IU 
daily for typical adults during fall and winter months and year-
round for adults at high risk for vitamin D deficiency. Subse-
quently, the Family Physicians Inquiries Network in the United 
States published a pivotal report in response to this research 
finding, suggesting that double-dose vitamin D lowers cancer risk 
in women older than age 55  (Schumann & Ewigman, 2007).
It has been shown that vitamin D increases the apoptosis in 
the colorectal epithelium, thereby reducing the risk of develop-
ing colorectal neoplasia (Holt et al., 2002, 2006). Indeed, many 
cell types, including colorectal epithelial cells, contain vitamin 
D receptors (VDRs) and express 1-a-hydroxylase. These cells 
are, therefore, able to convert the circulating 25-OH-D into 
active 1-25-OH-D metabolite, which, in turn, binds to the cells’ 
own VDRs to produce an autocrine effect by inducing cell dif-
ferentiation and inhibiting proliferation, invasiveness, angiogen-
esis, and metastatic potentials (Giovannucci, 2006). Among a 
large number of published research articles on the relationship 
between vitamin D and various cancers, vitamin D’s effects on 
colorectal cancer risk reduction has been most widely studied 
and reported. Therefore, this evidentiary article will primarily 
focus on the vitamin D effect in colorectal cancer risk reduction 
with the goals of transforming scientific knowledge into clinical 
practice. The objectives are to examine the effect of vitamin D 
on colorectal cancer prevention and risk reduction and provide 
practical recommendations for clinicians to evaluate and treat 
vitamin D deficiency in patients, as well as optimize vitamin D 
status accordingly. 
Search Strategy
To retrieve the best evidence on vitamin D in colorectal 
cancer prevention and risk reduction, electronic searches were 
conducted in a variety of databases from 2002–2008 because, 
generally speaking, evidence from the most recent five-year pe-
riod is considered most relevant to research. An Ovid search was 
carried out through Cochrane Database of Systematic Reviews, 
Cochrane Central Register of Controlled Trials, MEDLINE®, and 
CINAHL® by using keywords vitamin D, 25 hydroxyvitamin D, 
or cholecalciferol; colorectal neoplasm; clinical trial; cohort 
studies; case-controlled studies; and epidemiologic studies. 
The PubMed database was searched using vitamin D, colorectal 
neoplasm, and clinical trial; vitamin D, colorectal neoplasm, 
and cohort studies; vitamin D, colorectal neoplasm, and 
case-controlled studies; and vitamin D, colorectal neoplasm, 
Definition of Terms
Vitamin D status, the prohormonal vitamin D representing the amount 
of vitamin D storage in the body, is measured by the serum 25-OH-D 
assay. Serum 25-OH-D levels less than 32 ng/ml (80 nmol/L) represent 
hypo-vitamin D, or vitamin D deficiency or insufficiency (Holick, 2007). 
25-OH-D (25-hydroxyvitamin D): 25-hydroxyvitamin D, known as 
25-hydroxycholecalciferol, is the main vitamin D metabolite circulating 
in plasma, consisting of 25-OH-D2 or 25-OH-D3, depending on its origin. 
25-OH-D represents the vitamin D storage status in the human body 
(Quest Diagnostics, 2008). 
1-25-OH-D (1-25-hydroxyvitamin D): In the kidney, 25-OH-D chang-
es into an active hormonal form of vitamin D called 1-25-OH-D. The ac-
tive form helps control blood levels of calcium and phosphate balance. 
1-25-OH-D level is highly controlled and regulated by the parathyroid 
hormone (MedlinePlus Medical Encyclopedia, 2007a).
Confidence interval (CI): a range of values within which the popula-
tion parameter is estimated to fall based on the statistic and the stan-
dard error (Munro, 2005) 
Hazard ratio (HR): a measure of how often a particular event happens 
in one group compared to how often it happens in another group over 
time. In cancer research, HR = 1 indicates that no difference exists in 
survival between the two groups; HR more than or less than 1 indicates 
that survival is better in one of the groups (National Cancer Institute, 
2008).
Interquartile range (IQR): the range of values extending from the 
25th to the 75th percentile (Munro, 2005)
Odds ratio (OR): the probability of occurrence over the probability of 
nonoccurrence (Munro, 2005)
Parathyroid hormone (PTH): is secreted by the parathyroid glands 
to regulate the amount of calcium and phosphorous available in the 
blood. The role of PTH includes raising the level of calcium in the blood, 
decreasing the level of phosphorous in the blood, and increasing the 
amount of active vitamin D available in the body (MedlinePlus Medical 
Encyclopedia, 2007b). 
Probability value (p value): in a statistical hypothesis test, the likeli-
hood of getting the value of the statistic by chance alone (Munro, 2005) 
Relative risk or risk ratio (RR): the risk given one condition versus 
the risk given another condition (Munro, 2005)
R2 (variance): Squared multiple correlation is the amount of variance 
accounted for the dependent variable by a combination of independent 
variables (Munro, 2005).
Clinical Journal of Oncology Nursing  •  Volume 13, Number 4  •  Optimizing Vitamin D Status to Reduce Cancer Risk E5
and epidemiologic studies. In addition, manual searches were 
conducted on reference lists of relevant articles. 
No systematic reviews or meta-analyses based on randomized 
trials were found. Thirty-five potential research reports were 
identified, including RCTs, cohort studies, case-control stud-
ies, and epidemiologic studies. The study interests regarding 
vitamin D and colorectal neoplasm consist of vitamin D intake 
from diet and supplements, sun exposure, serum 25-OH-D lev-
els, vitamin D receptor polymorphism, and clinical trials with 
vitamin D plus calcium intervention. 
Twenty-five articles were selected for this evidentiary review 
(see Table 1). The selection criteria were based on strengths of 
evidence grade: RCTs with vitamin D as the intervention (n = 
4); cohort or case-control studies using serum 25-OH-D level 
measurement as the indicator variable reflecting vitamin D 
status to assess association with colorectal neoplasm (including 
colorectal adenomas and colorectal cancers) (n = 11); and cohort 
or case-control studies measuring vitamin D intake from diet, 
supplements, or both to examine the association with colorectal 
neoplasm (n = 10). Studies on adenomas or colorectal polyps 
also were selected because adenomas occur prior to cancer 
development, making adenomas the true indicator of colorectal 
cancer risk. Ecologic studies were not included, as these studies 
provide only suggestive associations between regions or seasons 
and sun exposure as the vitamin D proxy. Several studies based 
on VDRs as the main vitamin D variables also were not included 
because VDRs are not well understood and are probably less 
practical from a clinical perspective. 
Analysis and Synthesis
The Rating System for Levels of Evidence (Melnyk & Fineout-
Overholt, 2005) was used to grade the research studies selected 
for this evidentiary review. There are seven levels of evidence in 
this rating system, with level I representing evidence from a sys-
tematic review or meta-analysis through level VII representing 
evidence from expert opinion and/or consensus groups (Melnyk 
& Fineout-Overholt). Most studies in this review were rated as 
level II (one well-designed RCT) or level IV (well-designed case 
control and cohort studies). For discussion purposes, the studies 
are grouped into three categories based on the major variable of 
study interest: RCTs with vitamin D as an intervention, cohort 
or case-control studies measuring 25-OH-D levels as the primary 
variable, and cohort or case-control studies measuring vitamin 
D intake from diet and supplements. 
Vitamin D as a Research Intervention  
in Randomized, Controlled Trials  
Lappe et al. (2007) conducted a four-year, population-based, 
placebo-controlled, three-arm RCT with 1,179 postmenopausal 
women to examine the efficacy of calcium alone versus calcium 
plus vitamin D on cancer incidence of all types. Results revealed 
that the group taking 1,100 IU of vitamin D plus 1,400–1,500 
mg of calcium daily had a 60% overall cancer risk reduction 
compared to the placebo group (risk ratio [RR] = 0.4, 95% con-
fidence interval [CI] 0.2–0.82, p = 0.01). Excluding cancer cas-
es in the first year yielded an even more dramatic reduction in 
risk of 77% (RR = 0.23, 95% CI 0.09–0.6, p < 0.005). Vitamin D 
plus calcium treatment accounted 5.5% of the overall variance 
(R2 = 0.055), with the number needed to treat to prevent one 
case of cancer equaling 20 patients. No difference existed 
in toxicity profile among the three groups. The major limita-
tions of this RCT are the short study duration of four years, 
relatively few cases of cancer diagnosis (a total of 50 cancer 
cases, 13 during the first year and 37 during the subsequent 
three years), and the fact that cancer incidence was the sec-
ondary outcome. 
In contrast, the double-blind, placebo-controlled Women’s 
Health Initiative (WHI) study with 36,282 postmenopausal 
women found that taking 1,000 mg of calcium plus 400 IU of 
vitamin D daily for seven years revealed no protective effect 
against colorectal cancer incidence as the secondary outcome 
(RR = 1.08, 95% CI 0.86–1.34, p = 0.51) (Wactawski-Wende et 
al., 2006). However, the nested study of 25-OH-D level measure-
ment at baseline did show that higher 25-OH-D levels were as-
sociated with less colorectal cancer risk (odds ratio [OR] = 2.53 
for the lowest quartile of less than 31 nmol/L compared with the 
highest quartile of 58 nmol/L or higher, p = 0.02).
The WHI study has been subjected to several criticisms as 
a result of vitamin D supplementation showing no protective 
effects against colorectal cancer risk. First, the vitamin D dose 
(400 IU per day) used in the study potentially was too low to 
raise 25-OH-D levels into a meaningful range for a colorectal 
cancer risk reduction because 400 IU per day did not correct 
the vitamin D deficient status (Holick & Giovannucci, 2006). 
Instead, it only raised the mean 25-OH-D level from baseline 
42 nmol/L (16.8 ng/ml) to 47 nmol/L (18.8 ng/ml), whereas the 
suggested 25-OH-D level needed to decrease colorectal cancer 
risk is above 80 nmol/L (32 ng/ml) (Gorham et al., 2007). 
Second, a poor adherence rate of less than 50% existed among 
WHI study participants. Third, the concurrent use of overlap-
ping estrogen therapy in the WHI study likely modified the 
effects of the calcium plus vitamin D regimen (Ding, Mehta, 
Fawzi, & Giovannucci, 2008). Ding et al. (2008) re-analyzed 
the primary data from the WHI study to focus on women 
concurrently taking supplemental estrogen. The hazard ratio 
(HR) of colorectal cancer for women concurrently taking 
calcium-vitamin D and estrogen was 1.5 (95% CI 0.96–2.33), 
which suggested increased risk. The HR of colorectal cancer 
for women taking calcium and vitamin D but concurrently as-
signed to the non-estrogen arm was 0.71 (95% CI 0.46–1.09), 
which indicated a possible protective benefit. The interaction 
between concurrent estrogen usage and calcium plus vitamin 
D supplementation was statistically significant (p = 0.02). 
Two small RCTs examined the effects of calcium plus vitamin 
D on the epithelial cell proliferation from colorectal mucosa and 
polyps (Holt et al., 2002, 2006). Findings demonstrated that 400 
IU of vitamin D plus 1,500 mg of calcium daily for six months de-
creased epithelial cell proliferation of the colorectal mucosa and 
colorectal polyp mucosa. Additionally, vitamin D plus calcium 
appeared to inhibit polyp formation. The anti-carcinogenic ef-
fect of vitamin D was supported by an in vitro study, as human 
colon cancer cells treated with vitamin D showed up-regulation 
of VDR and 25-hydroxyvitamin D-1-a-hydroxylase expression 
(Murillo, Matusiak, Benya, & Mehta, 2007). Previous case-
control studies also have demonstrated that vitamin D increases 
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Table 1. Studies Researching Vitamin D Deficiency
STuDy PuRPOSE
DESIgn  
AnD METHOD
SAMPlE  
AnD SETTIng MAjOR FInDIngS
lEVEl OF 
EVIDEnCE CRITIQuE
Vitamin D as a Research Intervention in RCTs
Holt et al., 
2002
To examine the 
relationship be-
tween serum lev-
els of 25-OH-D, 
1-25-OH-D, and 
the indices of 
colorectal epithe-
lium proliferation 
and differentia-
tion 
Three-arm RCT 
consisting of 
calcium (1,500 
mg daily), calcium 
(1,500 mg) plus 
vitamin D (400 
IU) daily, or 1-25-
OH-D 0.25 mcg 
bid; duration was 
six months.
139 outpa-
tients with his-
tory of polyps 
within three 
years from two 
hospitals in 
New York City 
The calcium plus vitamin D group 
(adding baseline dietary vitamin D 
equaling the total of 800 IU per day) 
increased 25-OH-D levels by 44% 
to 37 ng/ml. Epithelial cell prolifera-
tion decreased as serum 25-OH-D 
increased, suggesting local autocrine 
effects on circulating 25-OH-D. Cal-
cium appeared to enhance the effects 
of 25-OH-D. 
 II The study pro-
vided the biolog-
ic explanation 
for CRC control 
from circulating 
serum 25-OH-D. 
Holt et al., 
2006
To study the ef-
fects of calcium 
plus vitamin D 
on colorectal 
adenoma mu-
cosa changes 
measured by 
biomarkers
Two-arm RCT 
consisting of pla-
cebo or calcium 
(1,500 mg) plus 
vitamin D (400 
IU) daily; duration 
was six months.
19 outpatients 
with small  
polyps (less 
than 9 mm) 
from the popu-
lation of one 
New York City 
hospital 
Calcium plus vitamin D significantly 
decreased the proliferative indices of 
colorectal polyps, increased the VDR 
staining, and strikingly decreased the 
MUC5AC mucin staining (a prolifera-
tive marker). 
II The study 
provided the 
biological expla-
nation for CRC 
control effects 
of calcium plus 
vitamin D. 
Lappe et al., 
2007 
To determine 
the efficacy of 
placebo, cal-
cium alone, and 
calcium plus 
vitamin D in 
cancer incidence 
as the secondary 
outcome 
Three-arm RCT 
consisting of  
placebo, calcium 
(1,400–1,500 
mg), or calcium 
(1,400–1,500 mg) 
plus vitamin D 
(1,100 IU) daily; 
duration was four 
years.
1,179 commu-
nity-dwelling 
postmenopaus-
al women
Calcium plus vitamin D significantly 
increased 25-OH-D levels after 12 
months of intervention (from 71.8  
to 96 nmol/L); calcium plus vitamin D 
decreased cancer incidence by 60% 
(RR = 0.4, 95% CI 0.2–0.82, p = 
0.01) over four years. If first year was 
excluded, calcium plus vitamin D de-
creased cancer incidence by 77% (RR = 
0.23, 95% CI 0.09–0.6, p < 0.005).
II Cancer incidence 
was not the 
primary end 
point. The four-
year duration 
may not be long 
enough because 
of the latency 
period for cancer 
development.
Wactawski-
Wende et 
al., 2006 
Whether calcium 
(1,000 mg) plus 
vitamin D (400 
IU) daily helps 
prevent CRC (the 
second outcome)
Two-arm RCT 
consisting of pla-
cebo or calcium 
(500 mg) plus 
vitamin D (200 
IU) twice per day; 
duration was 
seven years.
36,282 na-
tionwide post-
menopausal 
women from 
the Women’s 
Health Initia-
tive study 
Calcium plus vitamin D was effective 
in reducing CRC risks (HR = 1.08, 
95%CI 0.96–1.34, p = 0.51), but the 
nested case-control analysis showed 
that higher baseline 25-OH-D levels 
had a trend of less CRC risk (OR = 
2.53 for the lowest quartile of less 
than 31 nmol/L compared with the 
highest quartile of more than 58 
nmol/L, p = 0.02).
II Vitamin D at 400 
IU per day may 
be too small to 
achieve a mean-
ingful effect. The 
treatment adher-
ence rate was 
low (less than 
50%).
Dose Response Between Serum 25-OH-D levels and CRC Risk 
Feskanich et 
al., 2004
To examine 
the risk of col-
orectal cancer 
in relation to 
serum vitamin 
D metabolites 
(25-OH-D and 
1-25-OH-D) 
Case-control co-
hort study 
193 cases from 
the Nurses’ 
Health Study; 
one CRC case 
matched with 
two health 
controls 
Serum 25-OH-D levels were inversely 
associated with CRC risks, comparing 
the top quartile of 35.3–44.5 ng/ml to 
the bottom quintile of 14.9–17.4 ng/
ml (OR = 0.53, 95% CI, 0.27–1.04, 
p = 0.02). No dose response existed 
between 1-25-OH-D levels and CRC 
risks.
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
Freedman et 
al., 2007
To examine the 
relationship 
between serum 
25-OH-D levels 
and cancer mor-
tality
Cohort study 
drawn from the 
Third National 
Health and Nutri-
tion Examination 
Survey
17,705 popu-
lation-based 
sample (older 
than age 17) 
in the United 
States 
Total cancer mortality was unrelated 
to baseline 25-OH-D levels. Baseline 
serum 25-OH-D levels of 80 nmol/L or 
greater were associated with a 72% 
risk reduction in CRC mortality (95% 
CI 0.32–0.89), compared with levels 
lower than 50 nmol/L (p = 0.02).
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled 
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort 
studies.
(Continued on next page)
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Table 1. Studies Researching Vitamin D Deficiency (Continued)
STuDy PuRPOSE
DESIgn  
AnD METHOD
SAMPlE  
AnD SETTIng MAjOR FInDIngS
lEVEl OF 
EVIDEnCE CRITIQuE
Giovannucci 
et al., 2006
To assess vita-
min D status 
with cancer 
incidence and 
cancer mortality 
Cohort study 
of male health 
professionals in 
the United States; 
duration was 14 
years.
47,800 men 
with 4,286 
diagnosed with 
cancer; 2,025 
died from 
cancer.
An increment of predicated 25 
nmol/L of 25-OH-D levels signifi-
cantly decreased CRC risk by 37% 
(RR = 0.63, 95% CI 0.48–0.83). For 
digestive system cancers, an incre-
ment of 25 nmol/L of predicted 25-
OH-D level significantly reduced the 
cancer incidence by 43% (RR = 0.57, 
95% CI 0.46–0.71), with a 45%  
reduction in cancer mortality  
(RR = 0.55, 95% CI 0.41–0.74). 
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
Grau et al., 
2003 
To assess the 
independent 
and joint effects 
of calcium and 
vitamin D status 
on colorectal 
advanced 
adenoma recur-
rence
Cohort study 
drawn from the 
Calcium Polyps 
Prevention Study
803 subjects 
with two sets 
of 25-OH-D 
levels from a  
multicenter 
study in the 
United States
Median 25-OH-D level was 29.1 ng/
ml. Higher 25-OH-D (more than 29.1 
ng/ml) and calcium acted jointly to 
decrease adenoma recurrence (RR = 
0.71, 95% CI 0.57–0.89, p = 0.12). 
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design. 
Jacobs et al., 
2006 
To assess the 
relationship 
among serum 
25-OH-D levels, 
dietary intake 
of vitamin D, 
and colorectal 
adenoma recur-
rence.
Cohort study 
drawn from the 
Ursodeoxycholi-
cacid Multi-Clinic 
Trial 
211 adenoma 
cases and 508 
controls; out-
patients were 
from multiple 
clinics in Ari-
zona. 
The association between 25-OH-D 
levels and adenoma recurrence was 
stronger for women with higher 25-
OH-D levels (33 ng/ml) (OR = 0.59, 
95% CI 0.3–1.16) versus women 
with low levels (17.2 ng/ml) than for 
men (OR = 0.95, 95% CI 0.6–1.49). 
An overall moderate, nonsignificant, 
inverse association existed between 
25-OH-D levels and adenoma.
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
Miller et al., 
2005
To examine 
whether calcium 
and vitamin D 
are associated 
with increased 
apoptosis in nor-
mal rectal biopsy 
tissue
Cross-sectional 
study
498 outpa-
tients (174 
adenoma 
patients, 324 
nonadenoma 
patients) from 
an East Coast 
hospital 
High calcium intake (more than 739 
mg per day) increased the rectal apop-
tosis in patients with adenoma (OR = 
3.4, 95% CI 0.9–12.9). Higher serum 
25-OH-D levels (more than 34.9 ng/
ml) were strongly associated with the 
rectal epithelium apoptosis scores in 
patients free of adenoma (OR = 2.6, 
95% CI 1.1–6.2), but slightly lower 
in adenoma patients (p = 0.13) com-
pared with lowest tertile (less than 
20.9 ng/ml). 
IV The study 
provided the 
biological expla-
nation for CRC 
risk reduction. 
The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
Otani et al., 
2007
To investigate 
the association 
between serum 
25-OH-D levels 
and the risk of 
CRC 
Nested case-
control study 
38,373 popu-
lation-based 
sample from 
Japan with 375 
cancer cases 
and 750 con-
trols 
Serum 25-OH-D level was not signifi-
cantly associated with CRC risks in 
men and women. A suggestive inverse 
relationship existed in men. The low-
est quintile of 25-OH-D (22.9 versus 
32.1 ng/ml for men, 18.7 versus 27 
ng/ml for women) was associated 
with an elevated risk of rectal cancer 
in men (OR = 4.6, 95% CI 1–2) and 
women (OR = 2.7, 95% CI 0.94–7.6). 
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled 
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort 
studies.
(Continued on next page)
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Table 1. Studies Researching Vitamin D Deficiency (Continued)
STuDy PuRPOSE
DESIgn  
AnD METHOD
SAMPlE  
AnD SETTIng MAjOR FInDIngS
lEVEl OF 
EVIDEnCE CRITIQuE
Peters et al., 
2004 
To study the 
association of 
vitamin D levels 
with colorectal 
adenoma risk 
and the effects 
of calcium and 
HRT in relation 
to vitamin D on 
adenoma risk.
Nested case-
control study 
drawn from the 
Prostate, Lung, 
Colorectal, and 
Ovarian Cancer 
Screening Trial
772 cases and  
777 controls 
from a multi-
center study
Women had a significantly decreased 
risk for advanced adenoma (OR = 
0.27, 95% CI 0.11–0.69; p = 0.0002), 
comparing the highest quintile of 25-
OH-D levels (36.6–72.8 ng/ml) with 
the lowest quintile (6.8–19.2 ng/ml). 
No risk reduction was observed in 
men. HRT increased 25-OH-D levels, 
but no effect on adenoma risk reduc-
tion. 
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
Sieg et al., 
2006 
To assess the 
relationship 
among serum 
25-OH-D levels, 
colorectal ad-
enoma, and CRC 
risk 
Case-control 
study
203 adenoma 
cases, 98 CRC 
cases, and 239 
controls 
Patients with CRC had significantly 
lower 25-OH-D levels compared to 
controls (winter was 15 ng/ml versus 
23 ng/ml, p = 0.001; summer was 21 
ng/ml versus 29 ng/ml, p = 0.0007). 
Patients with adenoma had signifi-
cantly lower 25-OH-D levels in winter 
(24 ng/ml versus 29 ng/ml, p = 0.01). 
25-OH-D levels showed an inverse 
correlation to CRC stages. 
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
Wu et al., 
2007 
To study the 
association 
between serum 
25-OH-D levels 
and the risk of 
colorectal cancer
The National 
Health Profes-
sional Study, 
a nested case-
control study, and 
pooled analysis 
from the Nurses’ 
Health Study
18,225 health-
care profes-
sionals in the 
United States
Higher 25-OH-D levels significantly 
reduced colon cancer risk, comparing 
the highest (39.4 ng/ml) with the low-
est quintile (18.4 ng/ml) (OR = 0.46, 
95% CI 0.24–0.89, p = 0.005). Pooled 
analysis showed decreased CRC and 
colon cancer risks, compared the high-
est to lowest quintile (CRC was OR = 
0.66, 95% CI 0.42–1.05, p = 0.01; 
colon cancer was OR = 0.54, 95% CI 
0.34–0.86, p = 0.002). 
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
Vitamin D Intake and CRC Risk
Hartman et 
al., 2005 
To evaluate 
the association 
between calcium 
and vitamin 
D intake and 
recurrence of 
adenomatous 
polyps 
Cohort study 
drawn from the 
Polyps Prevention 
Trial; duration 
was four years.
2,079 par-
ticipants from 
a population- 
based sample 
in the United 
States 
Total vitamin D intake was inversely 
associated (although weakly) with ad-
enoma recurrence, fifth quintile (11.7 
mcg per day) versus first quintile (3.35 
mcg per day) (OR = 0.84, 95% CI 
0.62–1.13, p = 0.03). Supplemental 
calcium and vitamin D were inverse-
ly associated with adenoma recur-
rence (calcium user was OR = 0.82, 
95% CI 0.68–0.99; vitamin D user 
was OR = 0.82, 95% CI 0.68–0.99). 
Vitamin D was slightly stronger in 
preventing multiple polyp recurrences 
(OR = 0.73, 95% CI 0.53–0.99).
IV No 25-OH-D 
level. The study 
was not a RCT 
design and 
lacked causal 
effect.
Kesse et al., 
2005 
To study the 
association be-
tween intake of 
dietary calcium, 
phosphorus and 
vitamin D, dairy 
products, and 
the risk of ade-
nomatous polyps 
and CRC
Cohort study with 
a duration of 6.9 
years
74,524 popu-
lation-based 
French women 
aged 40–65 
years
The relative risk of adenoma and CRC 
decreased with high calcium intake. 
No association was found between 
dietary vitamin D intake and risk of 
colorectal tumors. 
IV 
Null finding 
 
90% of subjects 
had low D intake 
of less than 400 
IU per day. The 
study was not a 
RCT design and 
lacked causal 
effect. 
CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled 
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort 
studies.
(Continued on next page)
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Table 1. Studies Researching Vitamin D Deficiency (Continued)
STuDy PuRPOSE
DESIgn  
AnD METHOD
SAMPlE  
AnD SETTIng MAjOR FInDIngS
lEVEl OF 
EVIDEnCE CRITIQuE
Lin et al., 
2005 
To assess the 
intake of calcium 
and vitamin D in 
relation to CRC 
risk.
Cohort study 36,976 post-
menopausal 
women from 
the Women’s 
Health Initia-
tive sample
Total calcium and vitamin D intake 
(from diet and supplements) were 
not associated with the risk of CRC. 
IV 
Null finding
Low median 
vitamin D intake 
of 271 IU per day 
was unlikely to 
be meaningful. 
No 25-OH-D lev-
el. The study was 
not a RCT design 
and lacked 
causal effect. 
Martinez et 
al., 2002 
To assess wheth-
er calcium and 
vitamin D intake 
from diet and 
supplements is 
associated with 
risk of adenoma 
recurrence
Cohort study 
drawn from the 
Wheat Bran Fiber 
Trial 
1,304 men and 
women with 
polyps larger 
than 3 mm 
removed within 
three months 
in Arizona 
Dietary calcium intake and total 
calcium intake decreased adenoma 
recurrence. Dietary vitamin D (174 IU 
per day) was inversely (but weakly) 
associated with adenoma recurrence. 
No association was revealed for 
supplemental sources of vitamin D 
(400 IU per day) and total vitamin D 
intake (455 IU). 
IV Dose cutoffs for 
analysis are likely 
too low to detect 
differences. No 
25-OH-D level. 
The study was 
not a RCT de-
sign and lacked 
causal effect.
McCullough 
et al., 2003 
To examine the 
association be-
tween intake of 
calcium, vitamin 
D, and dairy 
products and the 
risk of CRC
Cohort study 
drawn from the 
Cancer Prevention 
Study II nutrition-
al study; duration 
was four years. 
60,866 men 
and 66,883 
women from 
a population-
based sample 
in the United 
States 
Higher total calcium intake from diet 
and supplements was associated with 
a marginally lower risk for CRC (for 
highest versus lowest quintiles, RR = 
0.87, 95% CI 0.67–1.12, p = 0.02). 
Supplemental calcium was more effec-
tive (RR = 0.69, 95% CI 0.49–0.96, 500 
mg per day versus none). Total vitamin 
D intake from diet and supplements 
was inversely associated with CRC risk 
(high quintile of more than 525 IU per 
day versus low quintile of 110 IU  per 
day; RR = 0.8, 95% CI 0.62–1.02, p = 
0.02), particularly in men (RR = 0.71, 
95% CI 0.51–0.98, p = 0.02).
IV For the effect of 
vitamin D intake, 
calcium intake, 
and dairy prod-
uct intake on 
CRC risk, no 25-
OH-D level was 
presented. The 
study was not a 
RCT design and 
lacked causal 
effect. 
Mizoue et 
al., 2008 
To investigate 
whether vitamin 
D intakes are 
associated with 
CRC risk 
Case-control 
study 
836 CRC cases 
and 861 con-
trols from two 
university hos-
pitals in Japan 
High calcium decreased CRC risk. 
Vitamin D intake (high quintile 488 
IU per day for women, 532 IU per day 
for men) was non-significantly in-
versely associated with CRC risk (p = 
0.12). High calcium plus high vitamin 
D plus high sun exposure had the 
greatest inverse association with CRC 
risk (RR = 0.38, 95% CI 0.21–0.68,  
p = 0.001). 
IV For vitamin D 
intake, calcium 
intake and sun 
exposure on CRC 
risk, no 25-OH-D 
level was pre-
sented. The study 
was not a RCT 
design and lacked 
causal effect.
Oh et al., 
2007 
To examine 
calcium and 
vitamin D intake 
in relation to 
distal colorectal 
adenoma risk 
Cohort study 48,115 women 
from the 
United States 
taking part in 
the Nurses’ 
Health Study 
Total calcium intake was weakly 
associated with reduced distal col-
orectal adenoma risk. Total vitamin 
D intake was weakly associated with 
reduced risk for distal colorectal ade-
nomas (RR= 0.79, 95% CI 0.63–0.99; 
p = 0.07), but more strongly with 
distal colon adenoma risk (RR = 0.67, 
95% CI 0.52–0.87, p = 0.004). 
IV For the affect of 
vitamin D intake 
and calcium in-
take on distal col-
orectal adenomas, 
no 25-OH-D level 
was presented. 
The study was 
not a RCT design 
and lacked causal 
effect. 
CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled 
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort 
studies.
(Continued on next page)
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colorectal epithelium apoptosis (Diaz, Paraskeva, Thomas, Bind-
erup, & Hague, 2000; Miller et al., 2005). 
An effective dosage of vitamin D to raise 25-OH-D levels above 
80 nmol/L (32 ng/ml) is critical in achieving cancer risk reduc-
tion. Previous investigators have demonstrated a dose-response 
relationship between cancer risk and 25-OH-D levels. Quantita-
tive pooled analyses from cohort studies reveal that correction 
of vitamin D deficiency to an optimal level of 33 ng/ml or higher 
(82.5 nmol/L) is associated with a 50% reduction in colorectal 
cancer risk (Gorham et al., 2007), while a level of 52 ng/ml or 
higher (130 nmol/L) is associated with a 50% beast cancer risk 
reduction (Garland et al., 2007). In the study by Lappe et al. 
(2007), vitamin D intake of 1,100 IU per day raised 25-OH-D 
levels from a baseline of 71.8 nmol/L to 96 nmol/L. However, 
in the WHI study, vitamin D intake of 400 IU per day was too 
Table 1. Studies Researching Vitamin D Deficiency (Continued)
STuDy PuRPOSE
DESIgn  
AnD METHOD
SAMPlE  
AnD SETTIng MAjOR FInDIngS
lEVEl OF 
EVIDEnCE CRITIQuE
Park et al., 
2007 
To examine the 
associations 
of calcium and 
vitamin D intake 
from foods and 
supplements 
with CRC risk
Cohort study 191,011 pop-
ulation-based 
multiethnic 
sample in the 
western United 
States
Total calcium intake significantly 
reduced CRC risk in men and women. 
Total vitamin D intake reduced CRC 
risk in men only (RR = 0.72, 95% CI 
0.51–1, p = 0.03). High dietary vita-
min D reduced CRC risk for women 
(RR = 0.78, 95% CI 0.63–0.96), par-
ticularly for those not taking supple-
ments (RR = 0.69, 95% CI 0.52–0.93, 
p = 0.03). Dairy products reduced 
CRC risk, particularly for those not 
taking supplements (for men, RR = 
0.77, 95% CI 0.59–1.01; for women,  
RR = 0.66, 95% CI 0.49–0.89). 
IV For vitamin D 
intake, calcium 
intake, and dairy 
products’ affect 
on CRC risk, no 
25-OH-D level 
was presented. 
The study was 
not a RCT de-
sign and lacked 
causal effect.
Slattery et 
al., 2004
To determine the 
effect of intake 
of calcium, vita-
min D, and dairy 
products on rec-
tal cancer, and 
the effect of the 
BSM I (a type of 
VDR) and poly-A 
VDR polymor-
phisms on rectal 
cancer risk 
Case-control 
study 
2,306 rectal 
cancer cases 
and 2,749 
controls from 
a population 
based in the 
western United 
States
Women’s rectal cancer risk was re-
duced with a high quintile of vitamin 
D intake of more than 8.3 mcg per 
day (OR = 0.52, 95% CI 0.32–0.85), 
high intake of low-fat dairy products 
(OR = 0.61, 95% CI 0.39–0.94), and 
high calcium intake (OR = 0.39, 
95% CI 0.24–0.64). High levels of 
sunshine exposure for participants 
younger than age 60 reduced rectal 
cancer risk (OR = 0.62, 95% CI 
0.42–0.93).
IV For dietary cal-
cium, vitamin D, 
sunshine, and 
dairy products’ 
affect on rectal 
cancer risk, no 
25-OH-D level 
was presented. 
The study was 
not a RCT de-
sign and lacked 
causal effect. 
Theodoratou 
et al., 2008 
To evaluate the 
associations 
between CRC 
risk and the 
intake of vitamin 
D and calcium; 
to investigate 
whether any 
association is 
mediated via the 
VDR pathway
Case-control 
study 
A population-
based sample 
in Scotland 
with 2,070 
CRC cases and  
2,793 controls 
Dietary vitamin D intake and total 
vitamin D intake were significantly, 
inversely associated with CRC risk, 
with a 20%–23% reduction for high 
(6–8.31 ug/d) versus low (2.51–2.76 
mcg/d). Additional meta-analyses of 
serum 25-OH-D from previous studies 
showed an inverse association be-
tween 25-OH-D and CRC risk (OR = 0.7, 
95% CI 0.56–0.87), suggesting the 
association was mediated through 
the vitamin D binding to the VDR.
IV The study failed 
to demonstrate 
causal effect be-
cause of a lack 
of RCT design.
CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled 
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort 
studies.
low to raise 25-OH-D levels above 80 nmol/L to achieve any 
meaningful cancer risk reduction. Given these mixed results, a 
RCT in a large sample using an effective vitamin D dose to keep 
25-OH-D level within the range of 32–100 ng/ml (measured 
twice a year in both winter and summer) over 10 years is needed 
to provide the strongest evidence of vitamin D’s long-term ef-
fects in cancer risk reduction. 
Dose Response Between 25-OH-D level  
and Colorectal Cancer Risk 
Eleven studies based on cohort and case-control research 
designs examined the relationship between serum 25-OH-D 
levels and colorectal cancer risk. Seven of the studies showed 
various degrees of risk reduction for colorectal cancer and four 
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Four other studies examined serum 25-OH-D levels and 
colorectal adenoma risk. Jacobs et al. (2006) examined the 
sample cohort originating from the Ursodeoxycholicacid Trial 
for adenoma prevention and found a moderate, non-significant 
inverse association between 25-OH-D levels and adenoma re-
currence. Interestingly, Miller et al. (2005) revealed that higher 
25-OH-D levels were associated with higher rectal epithelium 
apoptosis for patients with or without adenomas. Peters et 
al. (2004) conducted a nested case-control study within the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening trial. 
Comparing the highest quintile (greater than 36.6 ng/ml) with 
the lowest quintile (19.2 ng/ml or lower) of 25-OH-D levels, the 
risk for advanced adenoma was decreased by 73% in women 
(OR = 0.27, 95% CI 0.11–0.69, p = 0.0002), but the risk was not 
decreased in men (OR = 1.1, 95% CI 0.6–2.05, p = 0.85). Again, 
serum 1-25-OH-D was not associated with advanced adenoma 
risk. Grau et al. (2003) assessed the cohort from the Calcium 
Polyp Prevention Trial and found a joint effect of 25-OH-D 
levels and calcium on adenoma recurrence. Only subjects 
with a 25-OH-D level above the median of 29.1 ng/ml and 
taking 1,500 mg of calcium daily demonstrated a statistically 
significant reduction for adenoma recurrence (RR = 0.71, 95% 
CI 0.57–0.89, p = 0.01). 
In summary, serum 25-OH-D levels, which represent vitamin 
D status, have consistently revealed an inverse relationship with 
colorectal cancer and colorectal adenoma risks. The lower the 
level, the higher the risk. The levels of 25-OH-D in Grau et al. 
(2003), Jacobs et al. (2006), Miller et al. (2005), and Peters et al. 
(2004) demonstrated a significant colorectal cancer or adenoma 
risk reduction in the range of 27–39.4 ng/ml, with a median of 
33 ng/ml. Such a level is well within the normal range of 32–100 
ng/ml for 25-OH-D levels.
Vitamin D Intake and Colorectal Cancer Risk
Ten studies measured the effect of vitamin D intake from diet 
and supplementation on colorectal cancer risk using cohort or 
case-control designs. Although level IV evidence is assigned 
for these studies, the measurement of vitamin D intake may 
not truly reflect vitamin D status because many factors affect 
such status, including age, obesity, physical activity, skin color, 
sunshine exposure, and smoking history (Holick, 2007). More-
over, the amount of vitamin D intake cannot be determined 
Patient Education Resources on Vitamin D Deficiency
Mayo Clinic: www.mayoclinic.com/health/vitamin-d/NS_patient-vitamind
Merck Manuals: www.merck.com/mmhe/sec12/ch154/ch154j.html
Vitamin D Council: www.vitamindcouncil.org
WebMD: www.webmd.com/food-recipes/features/are-you-getting-enough 
-vitamin-d?page=2&print=true
Video Clips on Vitamin D Deficiency
Vitamin D and cancer prevention: www.youtube.com/watch?v=1Psya
YNX1dw&feature=channel
What’s a vitamin D deficiency? www.youtube.com/watch?v=emj 
CzaHtSrg
for colorectal adenoma at higher serum 25-OH-D levels. The 
major limitations of the studies were that they were unable to 
demonstrate causal effects between vitamin D and colorectal 
cancer risk and that the 25-OH-D levels were mostly one-time 
measurements, which may not accurately represent vitamin 
D status because 25-OH-D levels f luctuate with seasonal 
changes. 
Seven studies evaluated the effects of serum 25-OH-D levels 
on colorectal cancer risk. A predictive model based on a cohort 
study indicated that every 25 nmol/L increase in 25-OH-D levels 
produces a 37% colorectal cancer reduction (RR = 0.63, 95% CI 
0.48–0.83) (Giovannucci et al., 2006). Wu et al. (2007) conducted 
a nested control study from the cohort of the Health Professional 
Follow-Up Study (HPFS), pooled the data with the Nurse Health 
Study (NHS) for analysis, and found a significant inverse relation-
ship for colon cancer risk between the highest and the lowest 
quintile of 25-OH-D levels in the HPFS cohort (fifth quintile = 39.4 
ng/ml and first quintile = 18.4 ng/ml, OR = 0.46, 95% CI 0.24–0.89, 
p = 0.005). The pooled analysis with the NHS showed signifi-
cantly decreased risks for total colorectal and colon cancer com-
paring the highest to the lowest quintile of 25-OH-D levels (total 
colorectal cancer OR = 0.66, 95% CI 0.42–1.05, p = 0.01; colon 
cancer OR = 0.54, 95% CI 0.34–0.86, p = 0.002). The third study 
of the NHS cohort alone (Feskanich et al., 2004) revealed that 
25-OH-D levels were inversely associated with colorectal cancer 
risk (fifth quintile versus first quintile OR = 0.53, 95% CI 0.27–1.04, 
p = 0.02). For women older than 60 years of age, the OR for col-
orectal cancer risk from the highest quintile of 25-OH-D levels 
was 0.35 (95% CI 0.14–0.87, p = 0.006), but no dose-response 
relationship was found between colorectal cancer risk and level 
of 1-25-OH-D (the hormonal form of vitamin D). Similarly, a case-
control study by Sieg et al. (2006) supported that higher 25-OH-D 
levels were associated with significantly lowered colorectal 
cancer risk. 
Otani, Iwasaki, Sasazuki, Inoue, and Tsugane (2007) con-
ducted a population-based, nested-control study of 25-OH-D 
levels and colorectal cancer risk in Japan and found the lowest 
quartile of 25-OH-D level was associated with an elevated risk 
of rectal cancer in men (lowest quartile of less than 23 ng/ml 
versus highest quartile of more than 32.1 ng/ml, OR = 4.6, 95% 
CI 1–20) and women (lowest quartile of less than 18.7 ng/ml 
versus highest quartile of more than 27 ng/ml, OR = 2.7, 95% CI 
0.94–7.6). However, Freedman, Looker, Chang, and Graubard 
(2007) examined the effect of 25-OH-D levels on cancer mor-
tality from the cohort of the Third National Health and Nutri-
tion Examination Survey and found no relationship between 
25-OH-D levels and total cancer mortality. However, 25-OH-D 
levels of 80 nmol/L (32 ng/ml) or higher were associated with 
a 72% reduction in colorectal cancer mortality (95% CI 32–89) 
compared with 25-OH-D levels of less than 50 nmol/L (p = 
0.02). Ng et al. (2008) analyzed the influence of prediagnosis 
serum 25-OH-D levels on colorectal cancer–specific mortality 
from the cohort of the HPFS and the NHS and reported that 
25-OH-D levels significantly reduced the overall mortality (low-
est quartile of less than 18.8 ng/ml versus highest quartile of 
more than 29ng/ml, HR = 0.52, 95% CI 0.29–0.94, p for trend 
= 0.02). A statistically nonsignificant trend existed toward 
improved colorectal cancer-specific mortality (HR = 0.61, 95% 
CI 0.31–1.19, p for trend = 0.23) 
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accurately because food survey questionnaires were used to 
estimate the amount of vitamin D intake for individuals.
Seven of the 10 studies revealed favorable findings regarding 
higher vitamin D intake and colorectal tumor risk reduction. For 
example, one population-based case-control study in Scotland 
found that vitamin D intake from diet and supplementation 
significantly reduced colorectal cancer risk (Theodoratou et al., 
2008). Another case-control study conducted in Japan reported 
that the combination of high vitamin D, calcium intake, and high 
sun exposures resulted in the greatest colorectal cancer risk 
reduction compared to each factor alone (Mizoue et al., 2008). 
Similarly, two additional studies demonstrated that high levels of 
vitamin D intake, increased consumption of low fat dairy prod-
ucts, or high levels of sunshine exposure decreased colorectal 
cancer risk (McCullough et al., 2003; Slattery et al., 2004). 
Interestingly, Park et al. (2007) examined vitamin D intake 
and colorectal cancer risk from a multiethnic cohort sample in 
California and Hawaii and found an inverse association between 
total vitamin D intake and colorectal cancer risk in men (RR = 
0.72, 95% CI 0.51–1, p = 0.03) but not in women (RR = 0.89, 95% 
CI 0.63–1.27, p = 0.8). However, women who had high vitamin D 
intake from foods showed a significantly lowered risk (RR = 0.78, 
95% CI 0.93–0.96), which was even more evident in women who 
did not take supplements (RR = 0.69, 95% CI 0.52–0.93, p = 0.03). 
Two studies assessed the effect of vitamin D intake on colorectal 
adenomas. One examined the NHS cohort and found that total 
vitamin D intake was weakly associated with reduced risk of com-
bined distal colorectal adenomas (RR = 0.79, 95% CI 0.63–0.99, 
p = 0.07), and more strongly associated with distal colon adenoma 
risk reduction (RR = 0.67, 95% CI 0.52–0.87, p = 0.004) (Oh, Wil-
lett, Wu, Fuchs, & Giovannucci, 2007). Another study investigated 
vitamin D intake on polyp recurrence from the cohort of the Pol-
yps Prevention Trial and determined that total vitamin D intake 
was inversely (although weakly) associated with adenoma recur-
rence, comparing the fifth to the first intake quintiles (OR = 0.84; 
95% CI 0.62–1.13, p = 0.03; for vitamin D supplementation, OR = 
0.82, 95% CI 0.68–0.99) (Hartman et al., 2005). Overall, vitamin D 
appeared to be more effective in preventing multiple recurrences 
of polyps (OR = 0.73, 95% CI 0.53–0.99) (Hartman et al.). 
Conversely, three studies did not find an inverse relationship 
between vitamin D intake and colorectal cancer risk. The first 
study examined the relationship between vitamin D intake and 
the risk of colorectal adenoma and colorectal cancer among a 
large group of French women (N = 74,524) with no association 
found between colorectal tumor and vitamin D intake after 
almost seven years of follow-up (Kesse, Boutron-Ruault, Norat, 
Riboli, & Clavel-Chapelon, 2005). However, this sample had 
a low consumption of vitamin D, with the 90th percentile of 
4.34 mcg per day (less than 400 IU per day). A second study 
conducted in the United States reported similar findings when 
analyzing vitamin D intake in the large WHI female cohort (N = 
36,976) (Lin et al., 2005). The median vitamin D intake of 271 
IU per day also was low in this sample (Lin et al., 2005). Like-
wise, Martinez, Marshall, Sampliner, Wilkinson, and Alberts 
(2002) assessed the effect of vitamin D intake from dietary and 
supplemental sources on colorectal adenoma recurrence among 
1,304 men and women who had polyps removed within three 
months of study entry. They were unable to detect any signifi-
cant impact of vitamin D intake on polyp recurrence after an 
average follow-up time of three years; however, the vitamin D 
dose for cutoff in this analysis also was low, about 400 IU per 
day. Therefore, low doses of vitamin D intake likely contributed 
to the non-significant results in colorectal cancer risk reduction 
in all three studies. 
In summary, the studies of vitamin D intake and colorectal 
tumor risk reveal inconsistent results. Vitamin D intake may 
only represent a portion of the overall vitamin D resource 
availability and is, therefore, unable to reflect true vitamin D 
status. In addition, vitamin D intake was estimated from food 
questionnaires, which were subject to measurement errors 
and recall biases. Moreover, different studies adopted different 
food questionnaires. Despite these limitations, higher vitamin 
D intake generally decreased colorectal tumor risk. 
Safety, Cost, and Benefits
Vitamin D intoxication (hypercalcemia and hyperphos-
phatemia) occurs when 25-OH-D levels reach 150 ng/ml (375 
nmol/L) (Holick, 2007). However, as described earlier, 1,100 IU 
per day of vitamin D revealed no difference in toxicity profile 
compared with placebo (Lappe et al., 2007). In Hathcock, Shao, 
Vieth, and Heaney (2007), subjects taking 10,000 IU per day 
of vitamin D for up to five months did not demonstrate toxic 
effects. In light of these findings, many experts are urging the 
Food and Nutrition Board of the Institute of Medicine to update 
the original vitamin D recommendation from 1997 because it 
no longer is supported by the evidence. The U.S. Food and Drug 
Administration (FDA) recommendations for vitamin D are 200 
IU per day for ages 19–50, 400 IU per day for age 51–70, and 600 
IU per day for ages 71 and older. 
Studies suggest that vitamin D intake should be around 1,000 IU 
per day to provide benefits for bone health and cancer risk reduc-
tion (Lappe et al., 2007; Vieth et al., 2007). Considering that more 
than 50% of Americans and about 80% of cancer survivors use 
dietary supplements without medical advice (Miller et al., 2008; 
Velicer & Ulrich, 2008), an evidence-based vitamin D recommen-
dation will help guide the general public regarding safety and 
quality-of-life outcomes. Grant, Garland, and Gorham (2007) esti-
mated that 1,000 IU per day of vitamin D would result in a 7%–9% 
absolute cancer reduction in the United States and a 14%–20% 
cancer reduction in Western Europe. In short, the overall health 
benefits of vitamin D greatly outweigh the potential risks (Grant 
& Garland, 2008). In fact, to date, no health risk associated with 
daily vitamin D intake of 1,000–2,000 IU has been reported. 
Regarding the financial savings associated with increased vita-
min D intake, the cost-to-benefit ratio can be calculated based on 
Lappe et al. (2007), which noted that treating 20 people prevents 
one cancer case over four years. The per-person cost of 1,000 IU 
per day of vitamin D is about $20 per year, or $80 for four years per 
person, which translates into $1,600 for 20 people over four years. 
In 2008, the overall cost for one cancer case was about $152,520, 
calculated from the estimated 1,437,180 cancer cases with a cost of 
$219.2 billion based on ACS (2008). Dividing the cost for one can-
cer case in 2008 ($152,520) by four years equals $38,130, meaning 
that for every $1,600 spent on vitamin D, a potential cost-saving of 
$38,130 in cancer treatment exists. This yields an excellent cost-
benefit ratio of 1:24 just from cancer alone. 
Clinical Journal of Oncology Nursing  •  Volume 13, Number 4  •  Optimizing Vitamin D Status to Reduce Cancer Risk E13
Suggested Recommendations 
Healthcare providers play important roles in disease pre-
vention, health promotion, and education. Because vitamin D 
deficiency is a widespread public health issue linked to cancer 
and other health risks, healthcare providers should not ignore 
this easily correctable condition. The FDA recommendations 
for vitamin D were set by the Institute of Medicine in 1997, but 
results from the WHI suggest that these recommendations are 
ineffective in preventing vitamin D deficiency as well as decreas-
ing the risk for osteoporotic fractures and colorectal cancer 
development (Jackson et al., 2006; Wactawski-Wende et al., 
2006). Higher vitamin D dosages of 700–1,100 IU per day used in 
previously cited RCTs resulted in 25-OH-D levels in the 80–100 
nmol/L range with subsequent reductions in fracture and cancer 
risks (Bischoff-Ferrari et al., 2005; Lappe et al., 2007). Previous 
studies also have clearly revealed that vitamin D status (25-OH-D 
level) and vitamin D intake are inversely associated with cancer 
Table 2. Treatment Recommendations for Vitamin D Deficiency 
RECOMMEnDATIOn RATIOnAlE
Encourage patients to take 
1,000 IU per day of vitamin D 
plus 1,200–1,500 mg of daily 
calcium if 25-OH-D levels are 
not available.
These supplemental amounts have been shown to reduce overall cancer risks, including risks for colorectal cancer 
(Gorham et al., 2007; Lappe et al., 2007) and fracture risks (Bischoff-Ferrari et al., 2005).
Screen 25-OH-D levels twice a 
year (near the end of summer 
and near the end of winter) 
for high-risk individuals.
Subclinical vitamin D deficiency (less than 32 ng/ml) is common in the general population, and the prevalence among 
patients with cancer and individuals with osteoporosis or osteopenia is alarmingly high (Everett, 2008; Hershman et 
al., 2006; Holick, 2007; Li et al., 2007; Lips et al., 2006; Maddipatla et al., 2007). Because 25-OH-D levels fluctuate with 
seasons because of sun exposure, measuring these levels twice a year provides more accurate assessment of vitamin D 
status (Freedman et al., 2007). Parathyroid hormone (PTH) levels also should be checked for individuals with osteopenia 
or osteoporosis and patients with metastatic bone disease. Vitamin D deficiency should be corrected prior to initiating 
bisphosphonate therapy to prevent hypocalcemia (Wang-Gillan et al., 2006; Yazbeck et al., 2007).  Individuals at high-
est risk of vitamin D deficiency include those with the following conditions or circumstances: cancer; osteoporosis and 
osteopenia; chronic kidney disease; liver disease; fibromyalgia; migraine headaches; gastrointestinal malabsorption, 
which often occurs after gastrectomy or gastric bypass procedures; Crohn disease; celiac spruce disease; people living in 
northern latitudes; older adults; young children; people who are homebound; people who have darker skin color; people 
who are obese or inactive; or people who are taking certain medications such as anticonvulsants, glucocorticoids, HIV/
AIDS treatments, and antirejection drugs after organ transplantation (Holick, 2007).
Correct vitamin D deficiency 
through vitamin D repletion.
Raising 25-OH-D levels within a range of 32–100 ng/ml results in numerous positive health outcomes, including 
stronger bones, colorectal cancer risk reduction, and increased muscle strength to reduce falls, which is particularly 
important for older adults (Bischoff-Ferrari et al., 2006). For every 40 IU (1 mcg) of vitamin D3, serum 25-OH-D levels 
increase by about 1 nmol/L (0.4 ng/ml) (Heaney et al., 2003). Very low levels of 25-OH-D may require prescription 
strength vitamin D (50,000 IU in D2 form in the United States). For 25-OH-D levels less than 20–32 ng/ml, consider 
50,000 IU of vitamin D2 weekly for four to five weeks; for 25-OH-D levels less than 15–20 ng/ml, consider 50,000 IU 
of vitamin D2 weekly for eight weeks (Lyman, 2005); and for 25-OH-D levels less than 15 ng/ml, consider 50,000 IU of 
vitamin D2 twice a week for five weeks (Adams et al., 1999). Recheck 25-OH-D levels one to two weeks after reple-
tion, with repetition of repletion based on the level-dose recommendations if 25-OH-D levels do not increase above 
32 ng/ml.a 
Maintain vitamin D at the suf-
ficient state with 25-OH-D lev-
els in the range of 32–100 ng/
ml; however, levels of 50–100 
ng/ml are optimal for most 
patient populations.a 
Without vitamin D maintenance after repletion, 25-OH-D levels will drop in two to four months because vitamin D 
has a half-life of one to two months (Vieth, 1999). The optimal 25-OH-D level of 50–100 ng/ml is preferred for colon 
cancer and breast cancer risk reduction (Garland et al., 2007; Gorham et al., 2007). Alternatively, Cannell and Hollis 
(2008) proposed that, for patients with serious illnesses associated with vitamin D deficiency such as cancer, heart 
disease, multiple sclerosis, diabetes, autism, and a host of other illnesses, doses should be sufficient to maintain 
year-round 25-OH-D levels from 55–70 ng/ml. Recommend a maintenance dose of 1,000 IU of vitamin D3 daily (Ly-
man, 2005). Because poor adherence to daily dosing is common, an alternative is to prescribe 50,000 IU of vitamin 
D2 once or twice per month (e.g., once a month in summer and twice per month in winter). Many patients prefer this 
approach with fewer pills. For those reluctant to take pills, recommend vitamin D rich foods, such as oily fish (e.g., 
salmon, tuna, canned sardines, mackerel), fortified foods, cod liver oil, and Shiitake mushrooms (Holick, 2007). 
Advise concurrent calcium 
intake of 1,200 mg daily for 
men and premenopausal 
women, and 1,500 mg daily 
for postmenopausal women 
and individuals with osteopo-
rosis or osteopenia. 
Calcium and vitamin D work jointly to promote strong bones and reduce cancer risk, as evidenced by the fact that 
most randomized, controlled trials have incorporated vitamin D and calcium as the intervention for cancer and frac-
ture risk reduction (Bischoff-Ferrari et al., 2005; Lappe et al., 2007). 
a For individuals with chronic granulomatous disorders, such as sarcoidosis and some lymphomas, 25-OH-D levels should be kept at lower range of 
20–30 ng/ml because of higher sensitivity to circulating 25-OH-D (Holick, 2007), primarily from the unregulated production of calcitriol (1-25-OH-D) 
from activated macrophage in sarcoidosis associated with a risk of hypercalcemia (Conron et al., 2000; Sharma, 2000). Individuals with primary hyper-
parathyroidism and chronic kidney disease associated vitamin D deficiency should be referred to a specialist in lieu of clinical management. 
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risks, particularly for colorectal cancer (Garland et al., 2006). 
Therefore, optimizing vitamin D intake provides “win-win” 
benefits of correcting vitamin D deficiency, promoting bone 
health, and reducing colorectal cancer risks. Based on currently 
available evidence, Table 2 outlines treatment recommendations 
for vitamin D deficiency. 
Implications and Conclusion
Although government healthcare agencies have not adopted 
any vitamin D recommendations for cancer risk reduction, 
current evidence is substantial and compelling and supports 
the role of vitamin D in reducing colorectal cancer risk. Nation-
ally and internationally, many experts are urging healthcare 
agencies and international food and nutritional boards to rec-
ommend an effective allowance for vitamin D intake (Veith et 
al., 2007). Ideally, more definitive evidence of vitamin D on 
any cancer risk reduction should be obtained through large, 
population-based, longitudinal RCTs with adequate doses of 
vitamin D as interventions. However, such trials are expensive, 
and sales of vitamin D, a rather low-cost supplement, cannot 
generate enough profits to offset the trial cost. However, the 
Vitamin D/Calcium Polyp Prevention Study (2004–2017), a 
double-blinded, four-arm RCT with 2,200 subjects, currently 
is underway to evaluate the effects of placebo, calcium (1,200 
mg per day), vitamin D (1,000 IU per day), and calcium plus 
vitamin D (1,200 mg plus 1,000 IU per day) on colorectal neo-
plasia risk reduction, but the result will not be available until 
after the study’s completion. (For more information on the 
trial, visit http://clinicaltrials.gov/ct2/show/NCT00153816.) 
In the meantime, vitamin D debates will continue regarding 
optimal vitamin D intakes, optimal vitamin D status, emerg-
ing roles of vitamin D, and so forth, adding the complexity of 
future vitamin D researches (Beres, 2008). 
Considering that more than 50% of Americans and 80% of 
cancer survivors are taking dietary supplements without clinical 
advice (Miller et al., 2008; Velicer & Ulrich, 2008), and acknowl-
edging the overall safety profile of vitamin D and its wide range 
of health benefits, recommending that patients take 1,000 IU of 
vitamin D daily is reasonable and practical and clinicians should 
make every effort to promote and maintain optimal vitamin D 
status in their patients. Above all, given that patient care is a multi-
faceted process, clinicians must consider the current research 
evidence, their patients’ condition and preferences, and their 
own experiences and judicious clinical judgment in addressing 
the need for vitamin D supplementation.
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This article has been identified as appropriate for a journal club.  When you read this article, think about how you would change 
your current practice regarding screening and managing vitamin D deficiency in your patients. See the Evidence-Based Practice 
column in the February 2009 Clinical Journal of Oncology Nursing (Vol. 13, No. 1, pp. 109–112) on how to implement and par-
ticipate in journal clubs. Photocopying of this article for discussion purposes is permitted.
1. What is the clinical practice question the authors are trying to answer?
2. Is the purpose of the article described clearly?
3. Is the literature review comprehensive and are major concepts identified and defined?
4. Are the clinical recommendations supported by evidence? What are they?
5. Do you currently screen patients for vitamin D deficiency? How do the clinical recommendations compare to your current 
practice? 
6. What practice change recommendations will you make based on the evidence presented in this article? Who should get 
screened for vitamin D deficiency? When, where, and how often should they be screened? How should someone be managed 
if deficient?
7. What patient education materials are available on this topic?  
journal Club Discussion Questions
